Skip to main content

Table 3 Survival data with prospective phase 2 trials and retrospective series

From: Chordoma: a case series and review of the literature

Phase 2 Trials Retrospective series
Treatment Lapatinib [12] Sorafenib [13] Imatinib [10] French Sarcoma Group [15] Imatinib [11] Pazopanib and sunitinib [16]
Number of cases 18 27 56 80 48 5
PFS (months) 8.2 NR 9 9.4 9.9 14
OS (months) 25 NR* 34.5 52.8 30 -
BORR (%) 0 3.7 2 6 0 20 (one patient)
  1. BORR best objective response rate, NR not reached but > 15 months, OS median overall survival, PFS median progression-free survival, * 12 months OS rate 86.5%